Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20740435 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL1604408 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL691739 | 0.95 | — | — | |
| SCHEMBL9008361 | 0.90 | — | — | |
| SCHEMBL24780851 | 0.79 | CYP3A4 (0.41) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL20335470 | 0.79 | NPSR1 (0.36) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL374351 | 0.77 | NPSR1 (0.52) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL7420059 | 0.75 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL758201 | 0.75 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL1604412 | 0.75 | SMN1; SMN2 (0.40) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391660-B2 | Heteroaromatic acetamide derivative, and preparation and use thereof | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-119735532-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-112824380-B | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024104956-A1 | SUBSTITUTED CYCLOALKYLSULFANYLPHENYLURACILS AND THEIR SALTS, AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024104954-A1 | SUBSTITUTED CYCLOALKYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| CN-112292129-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2007025943-A2 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1684752-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| US-7015329-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-21 | — | — | US | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005041959-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-05 | — | — | US | disclosed |
| US-4082913-A | ANTI-ATHEROSCLEROSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391660-B2 | Heteroaromatic acetamide derivative, and preparation and use thereof | TRPA1, TRPV1, TRPV5 | NPSR1 420/4885CYP4F2 866/4885CYP4A11 759/4885 |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | NPSR1 2723/4885CYP4F2 1004/4885CYP4A11 422/4885 |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | NPSR1 2415/4885CYP4F2 405/4885CYP4A11 134/4885 |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, G6PD | NPSR1 2653/4885CYP4F2 238/4885CYP4A11 83/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | NPSR1 2386/4885CYP4F2 173/4885CYP4A11 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.